Annual CFF
-$18.14 M
-$24.50 M-384.88%
31 December 2023
Summary:
Alaunos Therapeutics annual cash flow from financing activities is currently -$18.14 million, with the most recent change of -$24.50 million (-384.88%) on 31 December 2023. During the last 3 years, it has fallen by -$120.26 million (-117.76%). TCRT annual CFF is now -117.76% below its all-time high of $102.12 million, reached on 31 December 2020.TCRT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
$0.000.00%
30 September 2024
Summary:
Alaunos Therapeutics quarterly cash flow from financing activities is currently $0.00, unchanged on 30 September 2024. Over the past year, it has stayed the same.TCRT quarterly CFF is now -100.00% below its all-time high of $101.68 million, reached on 31 March 2020.TCRT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$0.00
$0.000.00%
30 September 2024
Summary:
Alaunos Therapeutics TTM cash flow from financing activities is currently $0.00, unchanged on 30 September 2024. Over the past year, it has increased by +$9.66 million (+100.00%). TCRT TTM CFF is now -100.00% below its all-time high of $160.83 million, reached on 31 March 2020.TCRT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TCRT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -384.9% | 0.0% | +100.0% |
| 3 y3 years | -117.8% | -100.0% | -100.0% |
| 5 y5 years | -145.0% | -100.0% | -100.0% |
TCRT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -117.8% | at low | -100.0% | +100.0% | -100.0% | +100.0% |
| 5 y | 5 years | -117.8% | at low | -100.0% | +100.0% | -100.0% | +100.0% |
| alltime | all time | -117.8% | at low | -100.0% | +100.0% | -100.0% | +100.0% |
Alaunos Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2024 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2024 | - | $0.00(0.0%) | -$11.98 M(-34.0%) |
| Dec 2023 | -$18.14 M(-384.9%) | $0.00(0.0%) | -$18.14 M(+87.7%) |
| Sept 2023 | - | $0.00(-100.0%) | -$9.66 M(-17.9%) |
| June 2023 | - | -$11.98 M(+94.5%) | -$11.77 M(-5732.1%) |
| Mar 2023 | - | -$6.16 M(-172.7%) | $209.00 K(-96.7%) |
| Dec 2022 | $6.37 M(-75.3%) | $8.47 M(-502.2%) | $6.37 M(-377.7%) |
| Sept 2022 | - | -$2.11 M(<-9900.0%) | -$2.29 M(-109.3%) |
| June 2022 | - | $0.00(0.0%) | $24.74 M(-0.1%) |
| Mar 2022 | - | $0.00(-100.0%) | $24.76 M(-3.9%) |
| Dec 2021 | $25.78 M(-74.8%) | -$186.00 K(-100.7%) | $25.78 M(-2.2%) |
| Sept 2021 | - | $24.93 M(>+9900.0%) | $26.36 M(+1701.9%) |
| June 2021 | - | $19.00 K(-98.1%) | $1.46 M(+0.5%) |
| Mar 2021 | - | $1.02 M(+154.3%) | $1.46 M(-98.6%) |
| Dec 2020 | $102.12 M(+72.6%) | $400.00 K(+1381.5%) | $102.12 M(-2.5%) |
| Sept 2020 | - | $27.00 K(+125.0%) | $104.75 M(-34.8%) |
| June 2020 | - | $12.00 K(-100.0%) | $160.61 M(-0.1%) |
| Mar 2020 | - | $101.68 M(+3255.8%) | $160.83 M(+171.9%) |
| Dec 2019 | $59.15 M(+46.7%) | $3.03 M(-94.6%) | $59.15 M(-39.3%) |
| Sept 2019 | - | $55.89 M(>+9900.0%) | $97.47 M(+134.4%) |
| June 2019 | - | $230.00 K(>+9900.0%) | $41.58 M(+1.3%) |
| Mar 2019 | - | $0.00(-100.0%) | $41.04 M(+1.8%) |
| Dec 2018 | $40.31 M(-11.0%) | $41.35 M(>+9900.0%) | $40.31 M(-2054.0%) |
| Sept 2018 | - | $0.00(-100.0%) | -$2.06 M(+0.0%) |
| June 2018 | - | -$304.00 K(-58.4%) | -$2.06 M(-104.6%) |
| Mar 2018 | - | -$731.00 K(-28.9%) | $44.54 M(-1.7%) |
| Dec 2017 | $45.30 M(-5848.6%) | -$1.03 M(<-9900.0%) | $45.30 M(-1.2%) |
| Sept 2017 | - | $1000.00(-100.0%) | $45.84 M(+0.0%) |
| June 2017 | - | $46.30 M(>+9900.0%) | $45.84 M(-4178.5%) |
| Mar 2017 | - | $29.00 K(-106.0%) | -$1.12 M(+42.6%) |
| Dec 2016 | -$788.00 K(-100.8%) | -$484.00 K(<-9900.0%) | -$788.00 K(-203.8%) |
| Sept 2016 | - | $0.00(-100.0%) | $759.00 K(-10.9%) |
| June 2016 | - | -$669.00 K(-283.3%) | $852.00 K(-59.2%) |
| Mar 2016 | - | $365.00 K(-65.7%) | $2.09 M(-97.9%) |
| Dec 2015 | $98.34 M(+759.4%) | $1.06 M(+1043.0%) | $98.34 M(-5.3%) |
| Sept 2015 | - | $93.00 K(-83.5%) | $103.82 M(-3.4%) |
| June 2015 | - | $565.00 K(-99.4%) | $107.44 M(+0.2%) |
| Mar 2015 | - | $96.61 M(+1374.8%) | $107.22 M(+837.1%) |
| Dec 2014 | $11.44 M(-79.0%) | $6.55 M(+76.8%) | $11.44 M(-80.4%) |
| Sept 2014 | - | $3.71 M(+964.9%) | $58.52 M(+6.4%) |
| June 2014 | - | $348.00 K(-58.4%) | $55.02 M(+0.6%) |
| Mar 2014 | - | $837.00 K(-98.4%) | $54.67 M(+0.2%) |
| Dec 2013 | $54.54 M(+11.3%) | $53.63 M(>+9900.0%) | $54.54 M(>+9900.0%) |
| Sept 2013 | - | $202.00 K(<-9900.0%) | $457.00 K(+63.8%) |
| June 2013 | - | -$1000.00(-100.1%) | $279.00 K(-26.8%) |
| Mar 2013 | - | $706.00 K(-256.9%) | $381.00 K(-99.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | $48.98 M(-41.9%) | -$450.00 K(-1975.0%) | $48.98 M(-0.7%) |
| Sept 2012 | - | $24.00 K(-76.2%) | $49.31 M(-0.3%) |
| June 2012 | - | $101.00 K(-99.8%) | $49.45 M(-19.7%) |
| Mar 2012 | - | $49.31 M(<-9900.0%) | $61.58 M(-27.0%) |
| Dec 2011 | $84.31 M(+168.2%) | -$120.00 K(-174.5%) | $84.31 M(+0.1%) |
| Sept 2011 | - | $161.00 K(-98.7%) | $84.19 M(+1.8%) |
| June 2011 | - | $12.23 M(-83.0%) | $82.70 M(-20.1%) |
| Mar 2011 | - | $72.04 M(<-9900.0%) | $103.47 M(+229.2%) |
| Dec 2010 | $31.43 M(-36.8%) | -$238.00 K(-82.2%) | $31.43 M(-59.1%) |
| Sept 2010 | - | -$1.33 M(-104.0%) | $76.83 M(-7.2%) |
| June 2010 | - | $33.00 M(>+9900.0%) | $82.77 M(+66.3%) |
| Mar 2010 | - | $2000.00(-100.0%) | $49.77 M(+0.0%) |
| Dec 2009 | $49.77 M(>+9900.0%) | $45.16 M(+880.7%) | $49.77 M(+980.7%) |
| Sept 2009 | - | $4.61 M(>+9900.0%) | $4.61 M(>+9900.0%) |
| June 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2008 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2008 | - | $0.00(0.0%) | $14.20 K(-60.1%) |
| June 2008 | - | $0.00(0.0%) | $35.60 K(0.0%) |
| Mar 2008 | - | $0.00(-100.0%) | $35.60 K(-99.9%) |
| Dec 2007 | $29.01 M(-15.4%) | $14.20 K(-33.6%) | $29.01 M(-0.0%) |
| Sept 2007 | - | $21.40 K(>+9900.0%) | $29.02 M(+0.1%) |
| June 2007 | - | $0.00(-100.0%) | $29.00 M(-54.2%) |
| Mar 2007 | - | $28.97 M(>+9900.0%) | $63.28 M(+84.5%) |
| Dec 2006 | $34.31 M(+104.6%) | $25.20 K(>+9900.0%) | $34.31 M(+0.1%) |
| Sept 2006 | - | $0.00(-100.0%) | $34.28 M(-0.0%) |
| June 2006 | - | $34.28 M(>+9900.0%) | $34.28 M(+104.5%) |
| Mar 2006 | - | $0.00(-100.0%) | $16.76 M(0.0%) |
| Dec 2005 | $16.76 M(+272.5%) | $100.00(-97.9%) | $16.76 M(+0.0%) |
| Sept 2005 | - | $4700.00(-100.0%) | $16.76 M(-21.1%) |
| June 2005 | - | $16.76 M(>+9900.0%) | $21.25 M(+372.9%) |
| Mar 2005 | - | $0.00(0.0%) | $4.49 M(-0.1%) |
| Dec 2004 | $4.50 M(+800.0%) | $0.00(-100.0%) | $4.50 M(-9.8%) |
| Sept 2004 | - | $4.49 M(>+9900.0%) | $4.99 M(+905.0%) |
| June 2004 | - | $0.00(-100.0%) | $496.60 K(-1.9%) |
| Mar 2004 | - | $6000.00(-98.8%) | $506.00 K(+1.2%) |
| Dec 2003 | $500.00 K(+4173.5%) | $490.60 K(>+9900.0%) | $500.00 K(+6566.7%) |
| Sept 2003 | - | $0.00(-100.0%) | $7500.00(-20.2%) |
| June 2003 | - | $9400.00(-594.7%) | $9400.00(-19.0%) |
| Dec 2002 | $11.70 K(+192.5%) | -$1900.00(-200.0%) | $11.60 K(-33.7%) |
| Sept 2002 | - | $1900.00(+216.7%) | $17.50 K(+12.2%) |
| June 2002 | - | $600.00(-94.5%) | $15.60 K(+4.0%) |
| Mar 2002 | - | $11.00 K(+175.0%) | $15.00 K(+275.0%) |
| Dec 2001 | $4000.00 | $4000.00(>+9900.0%) | $4000.00(>+9900.0%) |
| Sept 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2001 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2001 | - | $0.00 | $0.00 |
FAQ
- What is Alaunos Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Alaunos Therapeutics?
- What is Alaunos Therapeutics annual CFF year-on-year change?
- What is Alaunos Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Alaunos Therapeutics?
- What is Alaunos Therapeutics quarterly CFF year-on-year change?
- What is Alaunos Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Alaunos Therapeutics?
- What is Alaunos Therapeutics TTM CFF year-on-year change?
What is Alaunos Therapeutics annual cash flow from financing activities?
The current annual CFF of TCRT is -$18.14 M
What is the all time high annual CFF for Alaunos Therapeutics?
Alaunos Therapeutics all-time high annual cash flow from financing activities is $102.12 M
What is Alaunos Therapeutics annual CFF year-on-year change?
Over the past year, TCRT annual cash flow from financing activities has changed by -$24.50 M (-384.88%)
What is Alaunos Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TCRT is $0.00
What is the all time high quarterly CFF for Alaunos Therapeutics?
Alaunos Therapeutics all-time high quarterly cash flow from financing activities is $101.68 M
What is Alaunos Therapeutics quarterly CFF year-on-year change?
Over the past year, TCRT quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Alaunos Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TCRT is $0.00
What is the all time high TTM CFF for Alaunos Therapeutics?
Alaunos Therapeutics all-time high TTM cash flow from financing activities is $160.83 M
What is Alaunos Therapeutics TTM CFF year-on-year change?
Over the past year, TCRT TTM cash flow from financing activities has changed by +$9.66 M (+100.00%)